Achilles Therapeutics
ACHL
ACHL was delisted on the 20th of March, 2025.
18 hedge funds and large institutions have $19.4M invested in Achilles Therapeutics in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 7 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1% less capital invested
Capital invested by funds: $19.5M → $19.4M (-$123K)
1.46% less ownership
Funds ownership: 52.92% → 51.47% (-1.5%)
22% less funds holding
Funds holding: 23 → 18 (-5)
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$307K |
| 2 |
Millennium Management
New York
|
+$49.3K |
| 3 |
FA
Forefront Analytics
West Conshohocken,
Pennsylvania
|
+$48.9K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$45.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$13.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$1.45M |
| 2 |
Renaissance Technologies
New York
|
-$113K |
| 3 |
Jane Street
New York
|
-$40.8K |
| 4 |
CF
Cantor Fitzgerald
New York
|
-$36K |
| 5 |
VF
Virtu Financial
New York
|
-$28K |
ACHL Hedge Fund Activity: Q1 2023 in Review
18 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Achilles Therapeutics (ACHL) for Q1 2023, worth a combined $19.4M — down 0.63% from $19.5M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ACHL and 2 opened new positions — a net loss of 5 holders — while 2 trimmed existing stakes and 5 added.
The largest buyer was Morgan Stanley, opening a new position worth an estimated $307K. The largest seller was RA Capital Management, exiting entirely with an estimated $1.45M sold.
- 18 institutional investors held Achilles Therapeutics (ACHL) as of Q1 2023, down from 23 in Q4 2022.
- Funds reported $19.4M of Achilles Therapeutics stock for Q1 2023, down 0.63% quarter-over-quarter.
- 2 funds opened new Achilles Therapeutics positions in Q1 2023 and 7 closed out, a net change of -5 holders.
- The largest Achilles Therapeutics buyer in Q1 2023 was Morgan Stanley, an estimated $307K added.
- The largest Achilles Therapeutics seller in Q1 2023 was RA Capital Management, an estimated $1.45M sold.
Based on aggregated 13F filings for Q1 2023.